# Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

Source: [science.org](https://www.science.org/doi/abs/10.1126/sciadv.aed0035?af=R) · 2026-11-20 · Life
Page: https://themorning.science/story/immune-infiltrate-predicts-response-to-pd1-ctla4-but-not-pd1-and-distinguishes-p-7c108b97faac2572
Kind: research · Impact: medium

## In brief

- A Science Advances study finds that the immune infiltrate in metastatic melanoma predicts response to combined anti-PD1 and anti-CTLA4 checkpoint blockade.
- The immune infiltrate does not predict response to anti-PD1 alone.
- The study distinguishes programs of primary resistance in metastatic melanoma.

## Why it matters

It suggests that tumour immune infiltrate may help identify which metastatic melanoma patients are likely to respond to combined checkpoint blockade, a question that bears on treatment choice.

## Timeline

- 2026-11-20: Published in Science Advances, volume 12, issue 47

## Coverage

- [Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma](https://www.science.org/doi/abs/10.1126/sciadv.aed0035?af=R) — science.org, 2026-11-20

Tags: melanoma, immunotherapy, checkpoint blockade, immune infiltrate, cancer biomarkers

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
